# US 2012/0251439 A1 · Antigens Associated with Inflammatory Bowel Disease Including Ulcerative Colitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251439 A1
- Document ID: US20120251439A1
- Status: Published application
- Kind: A1
- Application number: 13/473,353
- Filed: 2012-05-16
- Published: 2012-10-04
- Earliest claimed: 2009-01-07
- Inventors: Kathrin Schwager
- Web page: https://patentgrep.com/patent/US20120251439A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 51/1018: {against material from animals or humans}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of inflammatory bowel disease such as ulcerative colitis and/or for use in delivery to the neovasculature of intestinal tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of ulcerative colitis and/or for use in delivery to the neovasculature of inflammatory bowel disease tissue of a molecule conjugated to the specific binding member.

## Claims

### Claim at position 1

1-86. (canceled)

### Claim 87

A method of detecting or diagnosing inflammatory bowel disease in a human or animal, wherein the method comprises the steps of
(a) administering a specific binding member which binds the ED-A domain of fibronectin; and
(b) determining the presence or absence of the specific binding member in sites of bowel inflammation in the human or animal body; wherein localization of the specific binding member to sites of inflammation indicates the presence of inflammatory bowel disease in said human or animal.

### Claim 88 (depends on 87)

The method of claim 87, wherein the specific binding member is conjugated to a detectable label or a radioisotope.

### Claim 89 (depends on 88)

The method of claim 88 comprising imaging said site of inflammation.

### Claim 90 (depends on 87)

The method of claim 87, wherein the specific binding member comprises a VH domain comprising a framework and a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein HCDR1 has amino acid sequence SEQ ID NO: 42, HCDR2 has amino acid sequence SEQ ID NO: 56, HCDR3 has amino acid sequence SEQ ID NO 60; or wherein the VH domain comprises a set of complementarity determining regions having ten or fewer amino acid substitutions within the complementarity determining regions HCDR1, HCDR2 and HCDR3.

### Claim 91 (depends on 90)

The method of claim 90, wherein the VH domain framework is a human germline framework, and wherein the VH domain optionally has amino acid sequence SEQ ID NO: 14 or 16.

### Claim 92 (depends on 87)

The method claim 87, wherein the specific binding member further comprises a VL domain comprising a set of complementarity determining regions LCDR1, LCDR2 and LCDR3 and a framework.

### Claim 93 (depends on 92)

The method of claim 92, wherein LCDR1 has amino acid sequence SEQ ID NO: 102, LCDR2 has amino acid sequence SEQ ID NO: 114, and LCDR3 has amino acid sequence SEQ ID NO: 118; or wherein the VL domain comprises a set of complementarity determining regions having ten or fewer amino acid substitutions within the complementarity determining regions LCDR1, LCDR2 and LCDR3.

### Claim 94 (depends on 92)

The method of claim 92, wherein the VL domain framework is a human germline framework, wherein the VL domain optionally has amino acid sequence SEQ ID NO: 76 or 78.

### Claim 95 (depends on 92)

The method of claim 92, wherein the specific binding member comprises a single chain Fv.

### Claim 96 (depends on 95)

The method of claim 95, wherein the binding member is a small immunoprotein (SIP).

### Claim 97 (depends on 92)

The method of claim 92, wherein the specific binding member is a diabody.

### Claim 98 (depends on 87)

The method of claim 87, wherein said inflammatory bowel disease is ulcerative colitis and said binding member is anti-ED-A F8 antibody.

### Claim 99

A method of treating inflammatory bowel disease in a patient, the method comprising administering to a patient a therapeutically effective amount of a medicament comprising a specific binding member which binds the ED-A isoform of fibronectin.

### Claim 100 (depends on 99)

The method of claim 99, wherein the specific binding member is conjugated to a detectable label or a radioisotope.

### Claim 101 (depends on 99)

The method of claim 99, wherein the specific binding member is conjugated to a bioactive molecule, such as a cytokine, hormone, a therapeutic radioisotope or a cytotoxic drug, and wherein the bioactive molecule is optionally conjugated to the specific binding member by a cleavable linker.

### Claim 102 (depends on 99)

The method of claim 99, wherein said cytokine is selected from the group consisting of a cytokine selected from the group consisting of IL-10, TGF-beta, IL-2, IL-12, IL-15, IL-21, IL-24, IL-33, tumour necrosis factor (TNF), interferon-alpha, interferon-beta and interferon-gamma.

### Claim 103 (depends on 99)

The method of claim 99, wherein the specific binding member comprises a VH domain comprising a framework and a set of complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein HCDR1 has amino acid sequence SEQ ID NO: 42, HCDR2 has amino acid sequence SEQ ID NO: 56, HCDR3 has amino acid sequence SEQ ID NO 60; or wherein the VH domain comprises a set of complementarity determining regions having ten or fewer amino acid substitutions within the complementarity determining regions HCDR1, HCDR2 and HCDR3.

### Claim 104 (depends on 103)

The method of claim 103, wherein the VH domain framework is a human germline framework, and wherein the VH domain optionally has amino acid sequence SEQ ID NO: 14 or 16.

### Claim 105 (depends on 99)

The method claim 99, wherein the specific binding member further comprises a VL domain comprising a set of complementarity determining regions LCDR1, LCDR2 and LCDR3 and a framework.

### Claim 106 (depends on 105)

The method of claim 105, wherein LCDR1 has amino acid sequence SEQ ID NO: 102, LCDR2 has amino acid sequence SEQ ID NO: 114, and LCDR3 has amino acid sequence SEQ ID NO: 118; or wherein the VL domain comprises a set of complementarity determining regions having ten or fewer amino acid substitutions within the complementarity determining regions LCDR1, LCDR2 and LCDR3.

### Claim 107 (depends on 106)

The method of claim 106, wherein the VL domain framework is a human germline framework, wherein the VL domain optionally has amino acid sequence SEQ ID NO: 76 or 78.

### Claim 108 (depends on 99)

The method of claim 99, wherein the specific binding member comprises a single chain Fv.

### Claim 109 (depends on 108)

The method of claim 108, wherein the binding member is a small immunoprotein (SIP).

### Claim 110 (depends on 99)

The method of claim 99, wherein the specific binding member is a diabody.

### Claim 111 (depends on 102)

The method of claim 102, wherein said inflammatory bowel disease is ulcerative colitis and said binding member is anti-ED-A F8 antibody and said cytokine is IL-10.

### Claim 112 (depends on 109)

The method of claim 109, wherein the binding member is a small immunoprotein (SIP).
